Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Eribulin
Drug ID BADD_D00798
Description Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors [A7439].
Indications and Usage For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
Marketing Status approved; investigational
ATC Code L01XX41
DrugBank ID DB08871
KEGG ID D08914
MeSH ID C490954
PubChem ID 11354606
TTD Drug ID D0XQ5X
NDC Product Code Not Available
UNII LR24G6354G
Synonyms eribulin | E 7389 | E-7389 | ER-086526 | ER086526 | ER 086526 | ER-86526 | Halaven | NSC 707389 | NSC707389 | NSC-707389 | B 1793 | B-1793 | B 1939 | B-1939 | eribulin mesylate | eribulin monomethanesulfonate | eribulin mesilate | eribulin (as mesylate)
Chemical Information
Molecular Formula C40H59NO11
CAS Registry Number 253128-41-5
SMILES CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O 2)OC(C9OC)CC(CN)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fatigue08.01.01.002--
Febrile neutropenia08.05.02.004; 01.02.03.0020.010588%
Gastric ulcer07.04.03.0020.000112%
Gastric ulcer haemorrhage24.07.02.003; 07.04.03.0050.000112%Not Available
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.0040.000224%
Granulocytopenia01.02.03.0030.000168%Not Available
Haematemesis24.07.02.011; 07.12.02.0020.000112%Not Available
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
Headache17.14.01.001--
Hepatic cirrhosis09.01.04.0010.000280%Not Available
Hepatic failure09.01.03.0020.000560%
Hepatic function abnormal09.01.02.0010.000806%Not Available
Hepatic steatosis14.08.04.005; 09.01.07.0030.000437%Not Available
Hepatitis toxic12.03.01.016; 09.01.07.0170.000112%Not Available
Hepatocellular injury09.01.07.0080.000112%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.000392%Not Available
Herpes zoster23.11.05.005; 17.09.03.026; 11.05.02.003--
Hyperbilirubinaemia14.11.01.010; 09.01.01.003; 01.06.04.0030.000224%Not Available
Hypercalcaemia05.04.01.002; 14.04.01.0030.000224%
Hyperglycaemia14.06.02.002; 05.06.02.0020.000224%
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperpyrexia08.05.02.0020.000112%Not Available
Hypoaesthesia23.03.03.081; 17.02.06.0230.000772%Not Available
Hypoalbuminaemia14.10.01.002; 09.01.02.0030.000112%
Hypocalcaemia14.04.01.0040.000224%
Hypokalaemia14.05.03.0020.000392%
Hypomagnesaemia14.04.02.001--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 8 Pages